Ninety-two percent of biopharma M&A transactions realize their announced synergies when those synergies are validated and tracked from the letter of intent forward. The base rate without that discipline runs 14-40%. The difference is the 90 days after LOI. Most mid-cap biotech boards do not run those 90 days as a sprint. They treat the window as a transition period between term sheet and the first post-close earnings call.
The cost shows up in the deal record. AbbVie acquired Cerevel Therapeutics for $8.7 billion on August 1, 2024. Within four months, the lead asset, emraclidine, failed both Phase 2 schizophrenia trials. AbbVie took a $3.5 billion impairment in January 2025. The remaining Cerevel programs were valued at $3.6 billion: less than half the acquisition price, written down inside five months of close.
The integration did not cause the clinical failure. The absence of a 90-day contingency for the rest of the platform did. This is the checklist most boards are skipping.
Why boards skip the window
Four reasons recur.
The first is structural. Hart-Scott-Rodino clean-team requirements make most pre-close integration planning feel legally fraught. The FTC's February 2025 revisions to the HSR rules, the largest overhaul in 48 years, nearly tripled average filing preparation time. Counsel reads that as a reason to wait. It is the wrong reading. The extended window is the runway.
The second is cultural. In Doug Drysdale's March 2026 framing, "diligence that ends at the data room" is the precursor to most failed integrations. Diligence answers whether the asset is real. It does not answer whether two organizations can deliver the combined operating model.
The third is calendar. Board meetings run quarterly. The first post-close board meeting often lands 60-90 days after the press release, by which point the highest-leverage retention, CMC, and IT decisions have already been made or missed.
The fourth is leadership. Drysdale identifies a CEO who steps back after close as the third dominant failure mode. The CEO who signed the deal is the only person with the political capital to enforce the 90-day discipline. When that role disengages, the integration loses its top cover.
Days 1-15: the work that has to happen pre-close
The 30-to-60-day window between LOI and definitive agreement is the highest-leverage moment. McKinsey documents the shift: in 2019, 25% of acquirers planned their operating model before diligence; by 2022, 60% did. PMI Stack data shows companies that lack a dedicated integration leader at LOI are twice as likely to experience cost overruns. Spending is rising in tandem: in 2019, 6% of acquirers spent more than 10% of deal value on integration; by 2023, 21% did.
The work itself is concrete. Identify the key employees needing retention agreements; Mercer's M&A retention survey puts median stay bonuses at 25-95% of base salary, paid over 6-36 months post-close. Build the HR integration framework and the Day 1 org chart. Inventory IT systems and map a cutover pathway. Review customer contracts for assignment clauses and notification obligations. Audit suppliers. Stress-test the quality system: QMS, SOPs, CAPA frameworks. Plan FDA notification for CMC changes; for biologic manufacturers, the agency requires notification within 30 days of major process changes. Set up the financial consolidation framework and, critically, assign individual ownership for each synergy line item.
EY puts integration investment in life sciences at 10.1% of target revenue, well above the 5.6% average for technology. Acquirers who delay this work are more than twice as likely to overrun.
Days 16-45: the talent window
The second window is talent. MIT Sloan research found that 33% of workers acquired through M&A leave inside the first year, compared with 12% of comparable non-acquired hires. The Pioneer Management Consulting synthesis adds that 47% of key employees leave within a year and 75% within three. A 2025 EY study cited by the M&A Community put average post-merger turnover at 47% in year one.
Turnover peaks twice. The first peak is in the opening weeks, when uncertainty is highest and headhunters are most active. The second is 90-180 days after close, when the new organization takes shape and employees get an honest read of what working there will be like. The median executive retention period is 13-18 months, lining up with the typical retention bonus payout. Executives leave the day the checks clear.
McKinsey's February 2025 framework identifies four segments to protect: High Potentials, Value Creators (the owners of synergy-delivering initiatives), Influencers (the social-capital holders), and Mission-Critical Contributors (top salespeople and key technical leads). Titles do not predict segment membership. A senior manager with no direct reports can be the single Value Creator on a launch team.
The most visible 2024 example is Pfizer/Seagen. Within three months of close, Pfizer halted construction of Seagen's $350 million Everett biologics facility, displacing 120 employees. By April 2024, another 119 former Seagen employees were laid off. Angela Hwang, Pfizer's Chief Commercial Officer, departed after 27 years.
Days 46-75: operational hand-off
The hand-off is the most quietly destructive phase. Risk concentrates in CMC and IT.
Post-approval CMC changes in biologics require formal FDA notification across three categories: Prior Approval Supplements for major changes, Changes Being Effected supplements (CBE-30) for changes needing 30-day advance notice, and Annual Reports for minor changes. AVS Life Sciences flags validation and qualification alignment as one of the four highest-risk integration domains, noting that "GxP compliance failures during integration don't just create operational issues; they destroy the financial models used to justify acquisition premiums." For rare disease and oncology programs, a single gap can delay a BLA by 6-12 months.
The IT layer is worse on average. Gartner data compiled in the PMI Stack 2026 report puts the share of IT integrations that fail or experience significant issues at 84%. Of data migration projects, 83% fail or exceed budget. Full IT integration runs 12-18 months on the low end and 2-4 years for complex tech stacks. Half of synergy capture is linked to IT timing.
For cross-border deals, the hand-off compounds. BMS's May 2026 structure with Hengrui, a 13-program collaboration worth up to $15.2 billion that includes a bidirectional swap of US and China rights, sits inside that complexity. The cross-border BD framework that produces structures like it is the subject of the 2026 APAC outlicensing playbook; the integration question starts the day the term sheet is signed.
Days 76-90: the cost reconciliation
The last block is the cost reconciliation. Bain research documents that 70% of merging companies overestimate synergies at deal signing. The Global M&A Report's 2025 codification puts the revenue synergy gap at 5-10% projected growth against 2-4% realized: a 40-60% miss.
The 2024-2026 record makes the gap concrete. Pfizer announced its $43 billion Seagen acquisition in March 2023 with $3.1 billion in 2024 revenue and a $10 billion target by 2030. The October 2023 cost-realignment program started at $3.5 billion and expanded six times, reaching $7.7 billion by the end of Q1 2025. Activist Starboard Value took a $1 billion stake in October 2024 and publicly questioned Albert Bourla's stewardship.
BMS closed Karuna Therapeutics at $14 billion on March 18, 2024. Within six weeks, the company disclosed a separate $1.5 billion cost-cutting program with 2,200 layoffs and the discontinuation of 12 drug programs. Nine months later, BMS added another $2 billion. Two-thirds of the savings came from R&D.
Boards reading these arcs as one-time charges are reading them wrong. They are the visible part of a 90-day window the board did not run.
Three biopharma M&A failure modes
The 2024-Q2 2026 record converges on three modes.
The first is pipeline rationalization that loses key programs. BMS discontinued 12 drug programs in April 2024 as part of its post-Karuna restructuring, including CTLA4-, SIRPα-, and BET-targeting candidates. Recursion, three months into its Exscientia merger, terminated three clinical programs and paused a fourth, cutting its active pipeline from 11 to six. Najat Khan, Recursion's chief R&D officer, framed the cuts as "deliberate tradeoffs" toward areas of unmet need. In the disclosed deal record, rationalization decisions taken inside 90 days of close are rarely reversed.
The second is site closure that loses CMC expertise. Pfizer halting the Seagen Everett build cost 120 jobs and removed the institutional memory of the planned biologics platform. BMS shuttered its Illinois viral vector site, eliminating 133 positions and relocating production to Massachusetts. AVS Life Sciences notes that "in rare disease, manufacturing complexity amplifies the risk. Small patient populations mean production campaigns are highly specialized and leave little margin for error."
The third is commercial reorganization that loses momentum. Pfizer's restructuring after the Seagen close reorganized the commercial book under a new Oncology Division. Angela Hwang's departure after 27 years was the visible cost. McKinsey's 2025 culture report identifies organizational friction as the most common reason integrations miss value-creation targets.
The board's first post-close meeting: seven moves
Seven moves the board should ratify before the first quarterly cycle closes.
One. Appoint a single integration lead with budget authority, reporting directly to the CEO, before the closing wire moves. Companies without that lead at LOI are twice as likely to overrun.
Two. Lock retention before announcement. Mercer's range is 25-95% of base salary, paid in tranches over 6-36 months. Tier the bonuses by McKinsey's four segments, not by title. Include vesting acceleration on involuntary termination. Pay after close, not at close.
Three. Build a 90-day clean-team CMC and IT plan that survives FTC review. The February 2025 HSR overhaul nearly tripled prep time; the extended runway is the planning time. Inventory every CBE-30 and PAS event that close will trigger.
Four. Set a synergy tracking discipline with named owners, weekly reporting, and a board-level review at the 30, 60, and 90-day marks. The Bain 92% versus 14-40% gap is the only number that matters here.
Five. Run a pipeline rationalization model before close. Pre-commit which programs survive, which sunset, and which get partnered out. Post-close rationalization done without a model produces the BMS arc.
Six. Map the second-wave departure risk at the 90-180-day mark. Re-recruit then, not at the 12-month review. Median executive exit is 13-18 months; the time to bind them is months three and four.
Seven. Schedule the board's first post-close meeting at day 30, not at the next quarterly. The work that goes unmade in 90 days is rarely rebuilt later.
The bear case is real. It is also incomplete.
Roche bought Genentech for $43.7 billion in 2009 and chose minimal integration. Severin Schwan kept the South San Francisco research site independent, preserved the hiring model, and let the scientific culture stand. Biologics revenue tripled. Bain cites it as the canonical case where preserving target autonomy is the strategy, not the failure.
The 90-day checklist is not a template. It is a discipline. Doug Drysdale put the test plainly in March 2026: "The deals that failed didn't fail because of bad science or wrong pricing. They failed because integration was treated as a post-close project, not a pre-close strategy."
For a mid-cap biopharma board, the question is not whether to run the 90 days. It is whether the work happens before the press release or after the impairment.